Human Papillomaviruses (HPV) have double stranded DNA molecule of about 8000 base pair (bp) [1]. Human Papillomaviruses comprise over 200 distinct genotypes, which are classified into categories of low- and high-oncogenic risk types [1]. Low-risk (LR) types (LR-HPV6, 11, 34, 40, 42, 43, 44) predominantly present as benign genital warts, clinically referred to as condyloma, as well as laryngeal papilloma [3, 4]. In contrast, high-risk (HR) types, particularly HR-HPV16 and HR-HPV18, are etiologically linked to cervical cancer, vulvar, vaginal, anal, penile and oropharynx carcinomas [1], whereas other high-risk (HR) types such as 26, 30, 34, 53, 66, 67, 69, 70, 73, 82, 85, and 97 have been reported with low prevalence in cervical cancer cases [5]. The HPV family has been demonstrated to possess the capability to infect and transform epithelial cells [6]. Numerous investigations have documented the presence of human papillomavirus in the saliva of individuals diagnosed with oral cancer [7-12]. Additionally, the identification of human papillomavirus has been reported in dental clinical settings [13-15]. The E6 and E7 oncoproteins of human papillomaviruses exert critical influence in the pathogenesis of cancer by interfering with cell cycle regulation and inhibiting programmed cell death [16]. The E6 oncoprotein has the capacity to specifically interact with the cellular p53 protein, resulting in its degradation and subsequent reduction in concentration within cancerous cells [17].

Human papillomaviruses exhibit resistance to chemical disinfectants, such as glutaraldehyde solution and ortho-phthalaldehyde, and are only effectively inactivated by agents such as, hypochlorite, and PAA-silver-based disinfectants [18, 19].

Each year, high-risk (HR) human papillomavirus (HPV) groups account for approximately 630,000 novel oncological cases, with cervical cancer representing the majority at 530,000 instances, which equates to 4.5% of all human malignancies globally [20]. Furthermore, Low risk human papillomavirus (LR-HPV) serves as the causative agent for over thirty million cases of genital warts [18]. The predominant mechanism of mucosal HPV transmission occurs through intimate sexual interactions; nevertheless, non-sexual transmission of HPV may transpire through contaminated instruments such as colposcopes, colonoscopy devices, transvaginal ultrasound probes, endoscopes, and speculums [18]. Specifically, the contamination of fomites predominantly occurs during the course of clinical examinations. Consequently, the establishment of effective disinfection protocols is essential for the reduction of inadvertent HPV transmission.

There currently exists treatment for LR-HPV. The prevailing therapeutic approaches encompass podophyllotoxin [21], Imiquimod [22], Sinecatechins [23], intralesional/topical interferon [24], and topical 5-aminolevulinic acid (ALA) [25] for the management of genital and anal warts. The HPV vaccination initiative is effective solely against low-risk (LR) HPV and high-risk (HR) HPV types. The current treatment for HR-HPV is: with neoadjuvant cisplatin-based chemotherapy with high recurrent rate of 25-40% [26] and Multiple monoclonal antibodies (mAb) such as Ipilimumab, Pembrolizumab and Nivolumab for targeting of the PD-1 axis in cervical cancer [27].

Human Papillomaviruses (HPVs) are classified as DNA viruses that predominantly infect human hosts and are associated with various malignancies, most notably cervical carcinoma in females. The documentation of HPV infection has elucidated the involvement of HPVs in the pathogenesis of head and neck squamous cell carcinoma, esophageal carcinoma [28], cervical carcinoma [29], head and neck malignancies [30], as well as brain [31] and pulmonary neoplasms [32]. The identification of independent traditional risk factors, diverse clinical manifestations, and heightened prevalence among specific demographic groups and geographical locales has engendered a growing interest in the epidemiology of HPV infection.

The promotion of awareness and implementation of vaccination programs against HPV are of paramount importance, as a significant proportion of young adults remain uninformed regarding the associated risks and advantages of vaccination. The preventative HPV vaccines were formulated utilizing L1 protein derived from recombinant DNA technology. The immune response elicited by the vaccine was characterized by the production of neutralizing immunoglobulin G antibodies and the activation of cellular immunity [33]. The commercially available vaccines include Cervarix™ and Gardasil®.

These two vaccines differ in their formulations. The Gardasil® vaccine specifically targets HPV types including type 6, type 11, type 16, and type 18, and was approved in Europe and US [34]. The Gardasil®9 vaccine is designed to address five additional HPV strains (HPA31, HPA33, HPA45, HPA52, and HPA58) beyond the scope of the original Gardasil® vaccine. The introduction of a bivalent vaccine, which targets HPV 16 and HPV 18, occurred in both the United States and Europe in 2009 [35]. Administration of the 9vHPV vaccine has been shown to potentially avert 3% of laryngeal cancer cases, 4% of oral cavity cancers, 21% of oropharyngeal cancers, 23% of vulvar cancers, 25% of penile cancers, 61% of vaginal cancers, 79% of anal cancers, and 90% of cervical cancers [36]. As of June 2020, over 55% of World Health Organization member states had commenced HPV vaccination initiatives through national immunization programs. A growing body of research conducted across 22 nations has examined the effectiveness of the 9vHPV and 4vHPV vaccines in reducing the prevalence of HPV infections and associated disease in human populations [35, 37].

The family of human herpesviruses is characterized by enveloped double-stranded DNA genomes ranging from 125,000 to 240,000 base pairs in length. To date, only nine subtypes have been identified as having the capacity to infect humans (9). These include Herpes Simplex Viruses types 1 and 2 (HSV-1 and HSV-2), Varicella-Zoster Virus (HHV-3), Epstein-Barr Virus (EBV or HHV-4), Human Cytomegalovirus (HCMV or HHV-5), Human Herpesvirus types 6A and 6B (HHV-6A and HHV-6B), Human Herpesvirus-7 (HHV-7), and Kaposi’s Sarcoma-Associated Herpesvirus (HHV-8) [38].

These viruses cause disease, cold sores [39], genital herpes, stromal keratitis, malignancies [40], meningitis, and encephalitis [41, 42]. All herpesviruses undergo two distinct replication cycles: lytic and latent [42]. The lytic replication cycle culminates in the generation of viral particles that propagate infection to other cells and organisms, whereas the latent phase is characterized by restricted gene expression and the absence of infectious particles. Herpesviruses establish latency in various anatomical sites and have the potential to elicit disease during both the initial infection and subsequent reactivation; however, the underlying mechanisms that prompt latency and reactivation, remain inadequately understood [38].

Herpes viruses included, Herpes simplex virus type 1 (HSV-1 ) [43], Herpes simplex virus type 2 (HSV-2) [44], Epstein Barr virus [44], Human cytomegalovirus [45], Human Herpesvirus types 6 [46] and Human Herpesvirus types 8 [47] are transmitted via saliva of infected individuals during dental practice.

Both HSV-1 and HSV-2 are highly transmissible via saliva that propagate readily during active viral shedding [43, 44]. The presence of moist vesicles on the mucosal surfaces of the lips, oral cavity, and genital regions signifies an active infection. Both viruses undergo two distinct replication cycles: lytic and latent. during lytic cycle cause oral herpes or Cold sores, meningitis and encephalitis [41, 42]. Infections caused by HSV-1 and HSV-2 do not resolve spontaneously; rather, they persist as lifelong latent infections that may precipitate recurrent episodes [48]. The administration of antiviral medications can ameliorate the severity of reactivation episodes and diminish the likelihood of transmission [49]. HSV-1 was detected in dental clinic [50]. Although oral HSV-1 and HSV-2 infections are recognized within the context of dental practice, they garner comparatively less clinical attention due to their lower incidence among patients and the diagnostic complexities involved. At present no vaccine available against HSV-1 and HSV-2.

Varicella-zoster virus (VZV) represents a human alphaherpesvirus that is responsible for the manifestation of chickenpox (varicella) and shingles (herpes zoster) [75]. VZV possesses a linear, double-stranded DNA genome spanning approximately 125 kilobases, which encodes a minimum of 71 distinct proteins [51].

The transmission of chickenpox occurs via direct contact with the blisters, saliva, or mucus of an individual infected with the virus. Additionally, the virus may be disseminated through airborne particles resulting from coughing and sneezing. VZV has the potential to induce ulcerations within the oral cavity [38].

Varicella zoster virus (VZV) initiates varicella (commonly referred to as chickenpox) as the primary infection, while zoster (known as shingles) arises from the reactivation of the virus following latency within sensory ganglion neurons [52]. The complications associated with Varicella zoster virus encompass bacterial superinfection of the integumentary system, encephalitis, and pneumonia. Patients who present with zoster should receive prompt treatment with antiviral agents such as acyclovir, famciclovir, or valacyclovir, which are administered via the oral route [52]. VZV has been identified in a dental clinic setting [53]. Varicella vaccine available for children and adult [54].

Epstein–Barr virus (EBV), commonly identified as human gammaherpesvirus 4, represents a double-stranded DNA (dsDNA) virus categorized within the Herpesviridae family. The ubiquity of EBV within global populations can be attributed to its various transmission mechanisms and its capacity to integrate into the genomic structure of B cells, thereby facilitating persistent infections [55]. Transmission of EBV occurs predominantly through saliva, with the virus initially targeting the epithelial cells located in the oropharynx, nasopharynx, and tonsillar regions for its transcriptional and replicative processes, subsequently proceeding to infect B lymphocytes via specific envelope glycoproteins [56]. Following the initial infection, EBV transitions into a latent state, residing in resting memory B cells, where the replication of EBV is regulated by the host’s immune response. A decline in immune function can precipitate the reactivation of EBV, leading to a renewed lytic phase and the generation of infectious virions. This sequence of events prompts a new cycle of epithelial infection in the tonsils, accompanied by viral shedding in the saliva [57].

Approximately 35-50% of the adolescent demographic within the human population experiences the onset of infectious mononucleosis (IM), after which the virus remains latent throughout the individual’s lifespan [58]. Nevertheless, when the equilibrium between the virus and the host’s immune response is perturbed, Epstein-Barr virus (EBV) can instigate malignant transformation in both lymphoid and epithelial cells, resulting in approximately 200,000 fatalities each year [59].

The Epstein-Barr virus asymptomatically infects over 95% of healthy adults globally [60]. The Epstein-Barr virus (EBV) has been associated with the pathogenesis of a diverse array of human malignancies, which include Burkitt lymphoma, nasopharyngeal carcinoma, T/NK lymphoma, gastric cancers, B cell lymphoma, Hodgkin’s disease, certain T cell lymphomas, post-transplant lymphoproliferative disease, and, more recently, specific cancers affecting the stomach and smooth muscle [60, 61]. EBV was detected in patients with periodontal diseases in dental clinic [62]. Currently, there exists no targeted therapeutic intervention against EBV. Furthermore, there is neither an approved nor a therapeutic vaccine available for the Epstein-Barr virus.

Human cytomegalovirus belongs to Herpesviridae, or alternatively referred to as human herpesvirus-5 (HHV-5) [63]. Cytomegalovirus (CMV) is classified as a double-stranded DNA virus and is categorized within the herpesvirus family. This ubiquitous virus exhibits a spectrum of clinical manifestations, ranging from asymptomatic presentations to severe end-organ dysfunction, particularly in immunocompromised individuals suffering from congenital CMV disease [64]. Congenital cytomegalovirus infection has the capacity to induce significant morbidity and may even result in mortality [65].

While CMV infection may remain asymptomatic in immunocompetent individuals, it possesses the potential to be life-threatening for patients with compromised immune systems [65]. The saliva and urine of young children are major sources of virus [66]. In industrialized nations, CMV infects approximately 45% of the adult population, whereas in emerging countries, the infection rate approaches nearly 100% [67]. The presence of CMV constitutes a lifelong challenge characterized by antigenic T-cell surveillance and accompanying immune dysfunction [68]. Diseases causes by CMV in immunocompromised patients are, hepatitis, Graft rejection, vascular diseases, hepatitis, gastrointestinal ulceration, retinitis pneumoniae and autoimmune diseases [69, 70]. Subsequent to initial infection, CMV typically persists in a latent state; however, it is capable of reactivation at any point in time [69,70]. Ultimately, it has been implicated as a possible contributing factor in the development of breast, colorectal muscle, brain, and prostate cancers [71, 72]. Human cytomegalovirus was detected among patients in dental clinic [73]. CMV-specific hyperimmunoglobulin (CMVIG) as off-label therapy, valacyclovir, ganciclovir is used for CMV treatment [74]. Currently, no approved vaccine available to prevent Congenital cytomegalovirus infection.

Human herpesvirus 6 is categorized into two distinct entities, namely Human herpesviruses 6A and 6B (HHV-6A/6B; species Human betaherpesvirus 6A and Human betaherpesvirus 6B). HHV-6A/6B is a member of the Herpesviridae family [75]. Transmission of HHV-6A/6B occurs primarily through salivary secretions [76]. The mature CD4+ T cell serves as the primary target for HHV-6 infection. The virus exhibits pleiotropic influences on the immune system, notably including the modulation of natural killer cell functionality [77]. The occurrence of HHV-6A is notably more prevalent in individuals with compromised immune systems. Conversely, investigations have identified HHV-6B as the causative agent of the pediatric condition known as exanthema subitem (roseola infantum) [77]. HHV-6 is implicated in the etiology of acute febrile illnesses [77], hepatitis [78], encephalitis [79], and graft rejection phenomena [80]. Moreover, HHV-6 has been identified in the saliva of patients attending dental clinics [81].

In the context of patients undergoing stem-cell transplantation, the administration of Ganciclovir has shown significant therapeutic advantages and is regarded as the antiviral treatment of choice [82]. At present, there exists no FDA-approved therapeutic agent specifically designated for the treatment of HHV-6, nor is there a commercially available vaccine [83].

Influenza is classified by the World Health Organization (WHO) as a “serious global health threat” and accounts for a considerable number of fatalities on a global scale [84]. The Influenza A virus (IAV) and Influenza B virus, which are the primary etiological agents responsible for influenza, are classified within the Orthomyxoviridae family, characterized by segmented, negative-sense, single-stranded RNA viruses [85]. Among the various influenza viruses, the influenza A viruses (IAVs) are the most virulent and significant, being responsible for seasonal epidemics and all prior influenza pandemics [86]. The Influenza A virus is implicated in lower respiratory tract infections; it also possesses the broadest host range, highest morbidity and mortality rates, and is capable of inducing the most severe clinical manifestations [85]. The transmission of Influenza viruses occurs through saliva [87]. The presence of the Influenza virus has been identified in dental clinics [88]. The administration of Oseltamivir is associated with improved survival rates in hospitalized patients suffering from pneumonia caused by human influenza A/H3N2, A/H1N1, or B viruses [89]. Since dental students and dentists at risk of acquiring influenza infection, influenza vaccination program is a vital and shows very effectiveness against human influenza A/H3N2, A/H1N1, or B viruses. Dent team should receive a single dose of flu vaccine every year [90].

On March 11, 2020, the World Health Organization (WHO) formally declared the emergence of a pandemic associated with the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), presently referred to as COVID-19 [91]. The COVID-19 pandemic has precipitated significant global ramifications, impacting hundreds of millions of individuals and resulting in over six million fatalities [92].

Variants of the SARS-CoV-2 virus, namely Alpha, Beta, Delta, and the extensively mutated Omicron lineage, have instigated successive waves of infections following the global dissemination of the original strain since the year 2020 [93]. Omicron variants such as BA.2.86 and JN.1 exhibit in excess of 100 mutations that confer immune evasion capabilities. Specifically, Omicron BA.2.86 displays resistance to class 2 and 3 monoclonal antibodies targeting the receptor-binding domain, while also demonstrating a heightened receptor affinity in comparison to XBB.1.5 or EG.5.1. The novel subvariant BA.2.86, designated JN.1, manifests over 100 mutations relative to the wild type, indicative of a potential evolutionary divergence [94]. The transmission of SARS-CoV-2 occurs predominantly through the saliva of infected individuals [95]. Given that there exists no definitive therapeutic intervention for SARS-CoV-2 (COVID-19) [96], it follows that the COVID-19 vaccination initiative, encompassing mRNA vaccines, represents the sole effective strategy identified to mitigate the impact of SARS-CoV-2 [96, 97].

An essential mode of transmission within the dental practice is the direct contact with blood and bodily fluids [98]. Gingival bleeding often results in the presence of blood within saliva; consequently, it is imperative that all saliva be regarded as potentially infectious material [98]. Notable bloodborne pathogens of significance encompass the hepatitis B and C viruses, as well as the human immunodeficiency virus. The transmission of HBV within the field of dentistry occurs predominantly through percutaneous injury, which is associated with an average risk of HBV transmission estimated at 30%. The Hepatitis B virus is capable of retaining its infectious nature in desiccated blood at ambient temperature for a duration of one week [98].

The Hepatitis B virus is classified as an enveloped DNA virus and is a member of the Hepadnaviridae family [99]. An estimated 296 million individuals are currently afflicted with chronic Hepatitis B virus (HBV) infection on a global scale. Moreover, annual mortality attributed to liver cirrhosis and hepatocellular carcinoma (HCC) reaches approximately 820,000 individuals [99]. The transmission of HBV is facilitated through percutaneous injury, which is associated with an average risk of transmission amounting to 30% [98]. The presence of HBV among dental professionals has been documented in Iran [100]. Currently, entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and pegylated interferon (PEG-IFN) are preferred initial treatment for anti-HBV therapy [99]. The effective hepatitis B vaccine is available against hepatitis B virus which has declined significantly the rate of chronic HBV globally [101].

Post-exposure management for the hepatitis B virus (HBV) necessitates the administration of multiple doses of hepatitis B immune globulin (HBIG) in conjunction with the hepatitis B vaccine [101]. HBIG is a preparation of human immunoglobulin utilized to inhibit the onset of hepatitis B subsequent to acute exposure to the surface antigen of the hepatitis B virus (HBsAg) [102]. The antibody levels of the individual exposed should be evaluated if the source exhibits a positive HBsAg status. In instances where the exposed individual demonstrates a lack of immunity (i.e., has not been vaccinated, failed to achieve seroconversion post-vaccination, or has antibody titers to HBsAg below 10 mIU/mL), the recommended intervention is the administration of a single dose of HBIG within a timeframe of 48 to 72 hours post-exposure, alongside the initiation of the HBV vaccination series [101]. The HBV vaccine should be administered within a span of seven days following exposure, with subsequent doses given one or two months later, and then six months after the initial dose. The level of immunity should be assessed two to four weeks thereafter [101].

The risk of transmission of hepatitis B virus (HBV) exceeds 30% in situations where the source is positive and post-exposure prophylaxis is not administered [101, 102].

The Hepatitis C virus (HCV) is categorized as an enveloped positive-sense RNA virus and belongs to the Flaviviridae family [103]. HCV impacts over 170 million individuals worldwide and serves as a common etiological contributor to acute hepatitis, chronic hepatitis, and hepatocellular carcinoma [104]. Approximately 400,000 individuals worldwide perish as a result of HCV-related conditions each year [105]. The transmission of HCV primarily occurs via percutaneous injuries, such as needle sticks or exposure to blood, tissue, and other bodily fluids, which presents an average risk of HCV transmission estimated at 0.2% [106]. Evidence of HCV infection has been documented among dental professionals [107]. The emergence of safe and effective oral direct-acting antivirals (DAAs) for the treatment of hepatitis C holds significant promise for the potential eradication of Hepatitis C Virus [108]. Currently, there exists no approved vaccine for the prevention of Hepatitis C Virus infection [109].

Following exposure to the hepatitis C virus, it is imperative that the affected healthcare professional undergoes meticulous follow-up and is referred for suitable therapeutic interventions should infection be confirmed. Currently, there exists no efficacious post-exposure prophylaxis (PEP) for hepatitis C [101].

The probability of transmission subsequent to an injury inflicted by a positive source is contingent upon whether active viral replication is present. In instances where the source is negative for HCV RNA as determined by polymerase chain reaction (PCR) testing, the transmission risk ranges from 1.8% to 3.1%. Conversely, if the source is PCR positive, the transmission risk escalates to 10%. It is advisable to conduct testing at baseline, at three months, and at six months post-exposure. Additionally, liver function assessments, including aminotransferase (ALT) and aspartate aminotransferase (AST), are recommended at two, three, and six months. Continuous monitoring of clinical manifestations should be performed by an infectious disease specialist or gastroenterologist [101].

In June 2016, the World Health Organization (WHO) released its inaugural global health sector strategy, articulating the objective of eradicating viral hepatitis B and C as a significant public health concern by the year 2030 [110].

The human immunodeficiency virus (HIV) is an enveloped virus that consists of two positive single-stranded RNA molecules and is classified within the Retroviridae family [111]. To date, two distinct types of HIV, namely HIV-1 and HIV-2, have been identified [112]. The human immunodeficiency virus (HIV) constitutes a significant global public health challenge [111]. It was estimated that in the year 2019, approximately 38 million individuals were living with HIV, with an additional 1.7 million individuals newly diagnosed [113]. In the Islamic Republic of Iran, akin to numerous other nations, the incidence of HIV infection has escalated swiftly in recent years [114, 115]. Reports from the Iranian Ministry of Health and Medical Education indicated that 22,406 HIV-positive individuals resided in Iran in the year 2019 [116]. The primary mode of HIV transmission is through sexual contact, by maternal-infant exposure, percutaneous injuries [117]. At present, no definitive therapeutic interventions exist for HIV-1 and HIV-2 [117]. Furthermore, there is currently no licensed vaccine available for the prophylaxis of HIV infection [118].

The probability of seroconversion following a sharps injury involving HIV-contaminated blood is estimated at 0.3%, whereas the risk associated with exposure of mucous membranes to HIV-infected blood is quantified at 0.09% [119]. Consequently, it is imperative that post-exposure testing and medical evaluation are conducted.

In instances where the source may be infected with HIV, the consideration of post-exposure prophylaxis (PEP) is warranted. The primary objective of PEP is to inhibit viral replication. The fundamental regimen for HIV PEP typically incorporates zidovudine (ZDV) in conjunction with lamivudine (3TC). Alternatively, the regimen may consist of 3TC paired with stavudine, or didanosine combined with stavudine as appropriate. The enhanced regimen consists of the primary regimen supplemented with indinavir, nelfinavir, efavirenz, or abacavir [120].

The potential toxicity and adverse effects associated with HIV PEP warrant careful consideration. PEP is indicated solely in cases of substantial exposure, accompanied by a thorough risk assessment. Administration of the pharmacological agents should ideally occur within a timeframe of 24 to 36 hours following exposure [119]. Postexposure testing for HIV antibodies is recommended at baseline, six weeks, 12 weeks, and six months postexposure [120]. Follow-up includes reporting any sudden or severe flu-like symptoms, any adverse events associated with PEP if this is administered, as well as signs and symptoms of possible retroviral illness.

If the status of the source is unknown, decisions should be based on the exposure risk and the chance that the source may be HIV positive, e.g. an IV drug user. If the source consents to HIV testing, post-exposure prophylaxis can be given as soon as possible after exposure and discontinued if the result is negative [120].

Due to the inherent characteristics of their profession, dental practitioners encounter potential infectious agents on a daily basis, which constitutes a significant occupational hazard. It is imperative that vaccination protocols, appropriate utilization of personal protective equipment (PPE), as well as disinfection and sterilization guidelines, be meticulously adhered to in order to mitigate the transmission of infections [121]. Comprehensive protocols designed to reduce percutaneous injuries must be established within the dental practice, thoroughly elucidated to newly inducted personnel, and subject to regular review and assessment. In the event of an incident, a clearly defined exposure protocol and risk assessment should be implemented [101]. Infection control methodologies, ongoing educational initiatives, and vaccination efforts must be consistently emphasized, as both dental healthcare providers and their patients face the risk of infections and the potential for disease transmission. Effective sterilization techniques are essential to avert cross-contamination between patients [101, 121].

The critical significance of infection control must remain at the forefront of our considerations: during clinical interactions, while treating each patient, when transitioning between clinical activities, while processing dental instruments, and upon exiting the office toward home. This will minimize the risk of pathogens transmission and ensure patient and personnel safety.

Statement of Transparency and Principals:

• Author declares no conflict of interest

• Study was approved by Research Ethic Committee of author affiliated Institute.

• Study’s data is available upon a reasonable request.

• All authors have contributed to implementation of this research.

Suppl Suppl 1 03 2-23 25 Suppl 1 2015 10.1002/rmv.1822 Doorbar J Egawa N Griffin H Kranjec C Murakami I Reviews in Medical Virology Human papillomavirus molecular biology and disease association 2 02 172 12 2020 10.3390/v12020172 Wołącewicz M Becht R Grywalska E Niedźwiedzka-Rystwej P Viruses Herpesviruses in Head and Neck Cancers 4 639-649 14 2004 10.1111/j.1048-891X.2004.14418.x Huang H. J. Huang S. L. Lin C. Y. Lin R. W. Chao F. Y. Chen M. Y. Chang T. C. et al International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery 6 06 883.e1-17; quiz 899-900 66 2012 10.1016/j.jaad.2010.12.049 Gormley RH Kovarik CL Journal of the American Academy of Dermatology Human papillomavirus-related genital disease in the immunocompromised host: Part II 19 3 10 e00553 22 2022 10.34172/jrhs.2022.88 Shalchimanesh Z Ghane M Kalantar E Journal of Research in Health Sciences Prevalence of Human Papillomavirus Genotypes in Tehran, Iran 9 38 93 2010 Lyon IM IARC F 1995 U IARC Monogr Eval Carcinog Risks to Humans IARC monographs on the evaluation of carcinogenic risks to humans 01 5 05 1305 9 2020 10.3390/jcm9051305 Rapado-González Ó Martínez-Reglero C Salgado-Barreira Á Rodríguez-Fernández A Aguín-Losada S León-Mateos L Muinelo-Romay L López-López R Suarez-Cunqueiro MM Journal of Clinical Medicine Association of Salivary Human Papillomavirus Infection and Oral and Oropharyngeal Cancer: A Meta-Analysis 06 200237 13 2022 10.1016/j.tvr.2022.200237 Riddell J Brouwer AF Walline HN Campredon LP Meza R Eisenberg MC Andrus EC et al Tumour Virus Research Oral human papillomavirus prevalence, persistence, and risk-factors in HIV-positive and HIV-negative adults 21 6 09 1098-1108 226 2022 10.1093/infdis/jiac010 Zhang Y D'Souza G Fakhry C Bigelow EO Usyk M Burk RD Zhao N The Journal of Infectious Diseases Oral Human Papillomavirus Associated With Differences in Oral Microbiota Beta Diversity and Microbiota Abundance 1 01 e2337 33 2023 10.1002/rmv.2337 Wierzbicka M San Giorgi MRM Dikkers FG Reviews in Medical Virology Transmission and clearance of human papillomavirus infection in the oral cavity and its role in oropharyngeal carcinoma - A review 01 4 04 54 10 2022 10.3390/dj10040054 Kornhaber MS Florence T Davis T Kingsley K Dentistry Journal Assessment of Oral Human Papillomavirus Prevalence in Pediatric and Adult Patients within a Multi-Ethnic Clinic Population 04 99-106 59 2018 10.1016/j.meegid.2018.01.030 Hettmann A Demcsák A Bach Á Decsi G Dencs Á Pálinkó D Rovó L et al Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases Prevalence and genotypes of human papillomavirus in saliva and tumor samples of head and neck cancer patients in Hungary 10 18 09 4501 15 2023 10.3390/cancers15184501 Hinton H Coleman S Salem J. R. Kingsley K Cancers Screening for High-Risk Oral Human Papillomavirus (HPV31, HPV33, HPV35) in a Multi-Racial Pediatric and Adult Clinic Patient Population 03 7 04 780 12 2024 10.3390/healthcare12070780 JaKa MM Henderson MSG Gillesby AD Zibley LJ Basile SM Michalowicz BS Worley D et al Healthcare (Basel, Switzerland) "I'm Torn": Qualitative Analysis of Dental Practitioner-Perceived Barriers, Facilitators, and Solutions to HPV Vaccine Promotion 2 02 100-104 47 2020 10.1097/OLQ.0000000000001097 Stankiewicz Karita HC Magaret A Huang M Jerome KR Feng Q Wald A Sexually Transmitted Diseases Quantitative Oral HPV16 and HPV18 Detection in Persons Attending Dental Clinics 05 7 07 174 9 2017 10.3390/v9070174 Hoppe-Seyler K Mändl J Adrian S Kuhn BJ Hoppe-Seyler F Viruses Virus/Host Cell Crosstalk in Hypoxic HPV-Positive Cancer Cells 02 2 10 e21 6 2012 10.4081/oncol.2012.e21 Metgud R Astekar M Verma M Sharma A Oncology Reviews Role of viruses in oral squamous cell carcinoma 02 103222 64 2021 10.1016/j.ebiom.2021.103222 Boccardo E EBioMedicine New approaches for infective HPV detection, quantification and inactivation: Preventing accidental virus transmission in medical settings 6 06 1546-1550 69 2014 10.1093/jac/dku006 Meyers J Ryndock E Conway MJ Meyers C Robison R The Journal of Antimicrobial Chemotherapy Susceptibility of high-risk human papillomavirus type 16 to clinical disinfectants 15 4 08 664-670 141 2017 10.1002/ijc.30716 Martel C Plummer M Vignat J Franceschi S International Journal of Cancer Worldwide burden of cancer attributable to HPV by site, country and HPV type 6 06 829-845 100 2022 10.1007/s00109-022-02199-y Khairkhah N Bolhassani A Najafipour R Journal of Molecular Medicine (Berlin, Germany) Current and future direction in treatment of HPV-related cervical disease 8 08 1644-1653 34 2020 10.1111/jdv.16522 Gilson R. Nugent D. Werner R. N. Ballesteros J. Ross J. Journal of the European Academy of Dermatology and Venereology: JEADV 2019 IUSTI-Europe guideline for the management of anogenital warts 6 06 1371-1379 111 2008 10.1097/AOG.0b013e3181719b60 Tatti S Swinehart JM Thielert C Tawfik H Mescheder A Beutner KR Obstetrics and Gynecology Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial 1 02 21-29 94 2018 10.1136/sextrans-2017-053150 Westfechtel L Werner RN Dressler C Gaskins M Nast A Sexually Transmitted Infections Adjuvant treatment of anogenital warts with systemic interferon: a systematic review and meta-analysis 03 86-90 21 2018 10.1016/j.pdpdt.2017.11.005 Hu Z Liu L Zhang W Liu H Li J Jiang L Zeng K Photodiagnosis and Photodynamic Therapy Dynamics of HPV viral loads reflect the treatment effect of photodynamic therapy in genital warts 02 101945 83 2020 10.1016/j.ctrv.2019.101945 Marchetti C. Fagotti A. Tombolini V. Scambia G. De Felice F. Cancer Treatment Reviews Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis 23 12 2016 10.3892/mmr.2016.6073 Liu C Lu J Tian H Du W Zhao L Feng J Yuan D Li Z Molecular Medicine Reports Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity 1 01 1-20 167 2022 10.1007/s00705-021-05268-8 Geng H Xing Y Zhang J Cao K Ye M Wang G Liu C Archives of Virology Association between viral infection other than human papillomavirus and risk of esophageal carcinoma: a comprehensive meta-analysis of epidemiological studies 10 2 01 1320 24 2023 10.3390/ijms24021320 Martinelli M Giubbi C Saderi L Musumeci R Perdoni F Leone BE Fruscio R et al International Journal of Molecular Sciences Evaluation of Human Papilloma Virus (HPV) Genotyping and Viral Load Determination as Diagnostic Biomarkers of Cervical Cancer Risk 01 1 01 92-94 149 2023 10.1001/jamaoto.2022.3762 Garset-Zamani M Buchwald C Karevold G Agander TK Mateu-Regué À Eide HA Tvedskov JF JAMA otolaryngology-- head & neck surgery An HPV-Vaccinated Patient With Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma 01 1 01 102 11 2023 10.3390/vaccines11010102 Malik S Sah R Muhammad K Waheed Y Vaccines Tracking HPV Infection, Associated Cancer Development, and Recent Treatment Efforts-A Comprehensive Review 1 15-28 11 2022 10.1007/s13665-021-00283-1 Ramaswamy A Current Pulmonology Reports Lung Cancer Screening: Review and 2021 Update 11 11 11 1912 10 2022 10.3390/vaccines10111912 Akhatova A Azizan A Atageldiyeva K Ashimkhanova A Marat A Iztleuov Y Suleimenova A Shamkeeva S Aimagambetova G Vaccines Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State 01 5 03 E359-386 136 2015 10.1002/ijc.29210 Ferlay J Soerjomataram I Dikshit R Eser S Mathers C Rebelo M Parkin DM Forman D Bray F International Journal of Cancer Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 4 04 626-631 16 2023 10.1016/j.jiph.2023.02.014 Oyouni AAA Journal of Infection and Public Health Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines 4 10 pky045 2 2018 10.1093/jncics/pky045 Sanjosé S Serrano B Tous S Alejo M Lloveras B Quirós B Clavero O et al JNCI cancer spectrum Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58 03 106399 144 2021 10.1016/j.ypmed.2020.106399 Bruni L Saura-Lázaro A Montoliu A Brotons M Alemany L Diallo MS Afsar OZ et al Preventive Medicine HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019 25 10 5 2013 10.3402/jom.v5i0.22766 Grinde B Journal of Oral Microbiology Herpesviruses: latency and reactivation - viral strategies and host response 4 04 192-197; quiz 198 45 2024 Elkada L Ouanounou A Compendium of Continuing Education in Dentistry (Jamesburg, N.J.: 1995) Management of Oral Manifestations of Herpes Simplex Virus, Varicella Zoster Virus, and Human Papillomavirus 15 2 07 222-228 151 2022 10.1002/ijc.33987 Coghill AE Anna E. Kim Y Hodge JM Bender N Smith-Warner SA Teras LR Grimsrud TK Waterboer T Egan KM International Journal of Cancer Prospective investigation of herpesvirus infection and risk of glioma 10 12 12 2757 14 2022 10.3390/v14122757 Ahmed S Zalm P Rudmann EA Leone M Keller K Branda JA Steen J Mukerji SS Steen H Viruses Using CSF Proteomics to Investigate Herpesvirus Infections of the Central Nervous System 46 13 2019 10.3389/fncel.2019.00046 Duarte LF Farías MA Álvarez DM Bueno SM Riedel CA González PA Frontiers in Cellular Neuroscience Herpes Simplex Virus Type 1 Infection of the Central Nervous System: Insights Into Proposed Interrelationships With Neurodegenerative Disorders 24 8 02 2963-2967 106 2009 10.1073/pnas.0806660106 Shirtcliff EA Coe CL Pollak SD Proceedings of the National Academy of Sciences of the United States of America Early childhood stress is associated with elevated antibody levels to herpes simplex virus type 1 1 02 93-110 70 2016 10.1111/prd.12112 Corstjens PLAM Abrams WR Malamud D Periodontology 2000 Saliva and viral infections 01 08 107 8 2008 10.1186/1471-2334-8-107 Wilms IR Best AM Adler SP BMC infectious diseases Cytomegalovirus infections among African-Americans 3 09 159-165 2 2008 10.1016/S1976-1317(08)60039-0 Fukuda H Ichinose T Kusama T Sakurai R Asian Nursing Research Assessment of salivary human herpesvirus-6 and immunoglobulin a levels in nurses working shifts 23 2 01 338-340 18 2004 10.1097/00002030-200401230-00030 Mbopi-Keou F Legoff J Piketty C Hocini H Malkin J Inoue N Scully CM et al AIDS (London, England) Salivary production of IgA and IgG to human herpes virus 8 latent and lytic antigens by patients in whom Kaposi's sarcoma has regressed 09 81-91 522 2018 10.1016/j.virol.2018.07.011 Suzich JB Cliffe AR Virology Strength in diversity: Understanding the pathways to herpes simplex virus reactivation 2 02 208-215 101 2020 10.1099/jgv.0.001382 Bunz O Mese K Funk C Wulf M Bailer SM Piwowarczyk A Ehrhardt A The Journal of General Virology Cold atmospheric plasma as antiviral therapy - effect on human herpes simplex virus type 1 25 9 09 1737-1741 6 2018 10.3889/oamjms.2018.307 Ivanovska-Stojanoska M Popovska M Anastasovska V Kocova M Zendeli-Bedzeti L Dimova C Taseva A Open Access Macedonian Journal of Medical Sciences Detection of Virus Herpes Simplex Type 1 in Patients with Chronic Periodontal Disease 22 11 11023-11044 82 2008 10.1128/JVI.00777-08 Tillieux SL Halsey WS Thomas ES Voycik JJ Sathe GM Vassilev V Journal of Virology Complete DNA sequences of two oka strain varicella-zoster virus genomes 02 11 11 609 10 2018 10.3390/v10110609 Kennedy PGE Gershon AA Viruses Clinical Features of Varicella-Zoster Virus Infection 22 231 11 941-944 58 2020 10.31729/jnma.5310 Gurung D Joshi U Chaudhary B JNMA; journal of the Nepal Medical Association Orofacial Herpes Zoster Infection in Dental practice: A Case Report 05 10 10 1567 11 2023 10.3390/vaccines11101567 Bibi Z Nawaz AD Al Kurbi M Fakhroo S Ferih K Al-Jaber N Alex M et al Vaccines Real-World Effectiveness of the Varicella Vaccine among Children and Adolescents in Qatar: A Case-Control Study 1 10 75-82 1 2001 10.1038/35095584 Thorley-Lawson D. A. Nature Reviews. Immunology Epstein-Barr virus: exploiting the immune system 27 21 10 4995 10 2021 10.3390/jcm10214995 Buonavoglia A Leone P Prete M Solimando AG Guastadisegno C Lanave G Camero M et al Journal of Clinical Medicine Epstein-Barr Virus in Salivary Samples from Systemic Lupus Erythematosus Patients with Oral Lesions 623944 11 2020 10.3389/fimmu.2020.623944 Jog NR James JA Frontiers in Immunology Epstein Barr Virus and Autoimmune Responses in Systemic Lupus Erythematosus 27 21 05 1993-2000 362 2010 10.1056/NEJMcp1001116 Luzuriaga K Sullivan JL The New England Journal of Medicine Infectious mononucleosis 3 05 445-456 57 2020 10.1177/0300985820913265 Tillman H Vogel P Rogers T Akers W Rehg JE Veterinary Pathology Spectrum of Posttransplant Lymphoproliferations in NSG Mice and Their Association With EBV Infection After Engraftment of Pediatric Solid Tumors 4 04 1132-1139 110 2019 10.1111/cas.13954 Kanda T Yajima M Ikuta K Cancer Science Epstein-Barr virus strain variation and cancer 6 12 307-322 52 1999 10.1136/mp.52.6.307 Baumforth K. R. Young L. S. Flavell K. J. Constandinou C. Murray P. G. Molecular pathology: MP The Epstein-Barr virus and its association with human cancers 3 06 607-615 74 2024 10.1016/j.identj.2023.12.006 Zeng W Liu G Luan Q Yang C Luo X Zhu Z Yu X International Dental Journal Epstein-Barr Virus Promotes Inflammatory Cytokine Production in Human Gingival Fibroblasts 8414385 2018 2018 10.1155/2018/8414385 Mozaffar M Shahidi S Mansourian M Badri S Journal of Transplantation Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome? 8125806 2018 2018 10.1155/2018/8125806 Ngai JJ Chong KL Oli Mohamed S Case Reports in Ophthalmological Medicine Cytomegalovirus Retinitis in Primary Immune Deficiency Disease 2 02 143-158 73 2014 10.1097/NEN.0000000000000038 Teissier N Fallet-Bianco C Delezoide A Laquerrière A Marcorelles P Khung-Savatovsky S Nardelli J et al Journal of Neuropathology and Experimental Neurology Cytomegalovirus-induced brain malformations in fetuses 3 11 266-271 43 2008 10.1016/j.jcv.2008.07.012 Staras SAS Flanders WD Dollard SC Pass RF McGowan JE Cannon MJ Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology Cytomegalovirus seroprevalence and childhood sources of infection: A population-based study among pre-adolescents in the United States 31 4 10 213 8 2019 10.3390/pathogens8040213 Al Mana H Yassine HM Younes NN Al-Mohannadi A Al-Sadeq DW Alhababi D Nasser EA Nasrallah GK Pathogens (Basel, Switzerland) The Current Status of Cytomegalovirus (CMV) Prevalence in the MENA Region: A Systematic Review 05 5 09 673-685 202 2005 10.1084/jem.20050882 Sylwester AW Mitchell BL Edgar JB Taormina C Pelte C Ruchti F Sleath PR et al The Journal of Experimental Medicine Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects 12 12 759-773 19 2021 10.1038/s41579-021-00582-z Griffiths P Reeves M Nature Reviews. Microbiology Pathogenesis of human cytomegalovirus in the immunocompromised host 08 2 02 260 13 2021 10.3390/v13020260 Gugliesi F Pasquero S Griffante G Scutera S Albano C Pacheco SFC Riva G Dell'Oste V Biolatti M Viruses Human Cytomegalovirus and Autoimmune Diseases: Where Are We? 1202138 13 2023 10.3389/fcimb.2023.1202138 Chuan YU Suna HE Wenwen ZHU Penghui RU Xuemei GE Govindasamy K Frontiers in Cellular and Infection Microbiology Human cytomegalovirus in cancer: the mechanism of HCMV-induced carcinogenesis and its therapeutic potential 3 09 998-1002 170 2003 10.1097/01.ju.0000080263.46164.97 Samanta M Harkins L Klemm K Britt WJ Cobbs CS The Journal of Urology High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma 11 11 1847-1851 41 2015 10.1016/j.joen.2015.08.027 Jakovljevic A Andric M Knezevic A Soldatovic I Nikolic N Karalic D Milasin J Journal of Endodontics Human Cytomegalovirus and Epstein-Barr Virus Genotypes in Apical Periodontitis Lesions 08 12 06 3379 13 2024 10.3390/jcm13123379 Modrzejewska M Połubiński P Zdanowska O Journal of Clinical Medicine Ophthalmic Complications, Diagnosis, and Treatment of Congenital Human Cytomegalovirus Infection 5 05 863-870 159 2014 10.1007/s00705-013-1902-5 Ablashi D Agut H Alvarez-Lafuente R Clark DA Dewhurst S DiLuca D Flamand L et al Archives of Virology Classification of HHV-6A and HHV-6B as distinct viruses 21 09 e70452 10 2021 10.7554/eLife.70452 Wood ML Veal CD Neumann R Suárez NM Nichols J Parker AJ Martin D et al eLife Variation in human herpesvirus 6B telomeric integration, excision, and transmission between tissues and individuals 15 6 09 829-833 33 2001 10.1086/322691 Caserta M. T. Mock D. J. Dewhurst S. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America Human herpesvirus 6 8 10 533-534 39 2016 10.1016/j.gastrohep.2015.09.003 Arribas Anta J Zaera de la Fuente C Graus Morales J López Durán S Cañete Ruiz Á Gea Rodríguez F Albillos Martínez A Gastroenterologia Y Hepatologia [Fulminant hepatitis caused by herpes virus 6 in immunocompetent adults] 9 09 e11821 7 2014 10.5812/jjm.11821 Yavarian J Gavvami N Mamishi S Jundishapur Journal of Microbiology Detection of human herpesvirus 6 in cerebrospinal fluid of children with possible encephalitis 6 12 584-590 32 2019 10.1097/QCO.0000000000000592 Hill JA Current Opinion in Infectious Diseases Human herpesvirus 6 in transplant recipients: an update on diagnostic and treatment strategies 5 09 522-524 48 2023 10.30476/ijms.2023.97293.2911 Farahmand H Agha Sadeghi K Moattari A Farzin M Rakhshbahar H Esmaeili S Farajollahi A Iranian Journal of Medical Sciences Human Herpesvirus Detection in Removable Denture Wearers' Saliva Compared to Dentate Cases 12 148-153 9 2014 10.1016/j.coviro.2014.09.019 Prichard MN Whitley RJ Current Opinion in Virology The development of new therapies for human herpesvirus 6 1 01 217-245 18 2005 10.1128/CMR.18.1.217-245.2005 De Bolle L Naesens L De Clercq E Clinical Microbiology Reviews Update on human herpesvirus 6 biology, clinical features, and therapy The World Health Organization. Global Influenza Strategy 2019-2030. (2019). Available online at: https://www.who.int/influenza/Global_Influenza_Strategy_2019_2030_Summary_English.pdf?ua=1 (accessed September, 2020) 1-21 1836 2018 10.1007/978-1-4939-8678-1_1 Hutchinson EC Yamauchi Y Methods in Molecular Biology (Clifton, N.J.) Understanding Influenza 28 1 06 3 4 2018 10.1038/s41572-018-0002-y Krammer F Smith G JD Fouchier RAM Peiris M Kedzierska K Doherty PC Palese P et al Nature Reviews. Disease Primers Influenza 21 2 02 e0201023 90 2024 10.1128/aem.02010-23 Rockey NC Le Sage V Marr LC Lakdawala SS Applied and Environmental Microbiology Seasonal influenza viruses decay more rapidly at intermediate humidity in droplets containing saliva compared to respiratory mucus 9 09 1072, 1074 140 2009 10.14219/jada.archive.2009.0320 Glick M Journal of the American Dental Association (1939) Do dentists have a role in fighting the latest H1N1 pandemic? 25 6 06 e6051 4 2009 10.1371/journal.pone.0006051 Hanshaoworakul W Simmerman JM Narueponjirakul U Sanasuttipun W Shinde V Kaewchana S Areechokechai D Levy J Ungchusak K PloS One Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome 606242 7 2020 10.3389/fmed.2020.606242 Serban S Mustufvi Z Kang J Simon SE Grant S Douglas G Frontiers in Medicine The Dental Team: An Additional Resource for Delivering Vaccinations Coronavirus disease (COVID-2019) situation reports [internet]. [accessed May 21, 2020]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200520-covid-19-sitrep-121.pdf?sfvrsn=c4be2ec6_2 28 8 08 BSR20231395 44 2024 10.1042/BSR20231395 Al Adem K Ferreira JC Villanueva AJ Fadl S El-Sadaany F Masmoudi I Gidiya Y et al Bioscience Reports 3-chymotrypsin-like protease in SARS-CoV-2 3 06 767-786 52 2024 10.1007/s15010-024-02223-y Hattab D Amer MFA Al-Alami ZM Bakhtiar A Infection SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants 7992 12 639-644 624 2023 10.1038/s41586-023-06750-w Wang Q Guo Y Liu L Schwanz LT Li Z Nair MS Ho J et al Nature Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike 26 7 03 2225 17 2020 10.3390/ijerph17072225 Khurshid Z Asiri FYI Al Wadaani H International Journal of Environmental Research and Public Health Human Saliva: Non-Invasive Fluid for Detecting Novel Coronavirus (2019-nCoV) 09 1 04 40 10 2024 10.1038/s41421-024-00673-0 Zhang L Xie X Luo H Qian R Yang Y Yu H Huang J Shi P Hu i Cell Discovery Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04 8 08 914-921 23 2023 10.1016/S1473-3099(23)00122-6 Arbel R Peretz A Sergienko R Friger M Beckenstein T Duskin-Bitan H Yaron S Hammerman A Bilenko N Netzer D The Lancet. Infectious Diseases Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study 3 07 609-628, x 52 2008 10.1016/j.cden.2008.02.002 Thomas MV Jarboe G Frazer RQ Dental Clinics of North America Infection control in the dental office 01 2 06 83-90 8 2024 10.1016/j.livres.2024.05.004 Abdelhamed W El-Kassas M Liver Research Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do 5 05 307-316 17 2010 10.1111/j.1365-2893.2010.01284.x Mahboobi N. Agha-Hosseini F. Mahboobi N. Safari S. Lavanchy D. Alavian S.-M. Journal of Viral Hepatitis Hepatitis B virus infection in dentistry: a forgotten topic 1 01 2-7 9 2012 10.4103/1735-3327.92919 Ayatollahi J Ayatollahi F Ardekani AM Bahrololoomi R Ayatollahi J Ayatollahi A Owlia MB Dental Research Journal Occupational hazards to dental staff 6 06 379-394 43 2007 10.1358/dot.2007.43.6.1050792 Habib S Shaikh OS Drugs of Today (Barcelona, Spain: 1998) Hepatitis B immune globulin 546 8 2017 10.3389/fmicb.2017.00546 Fernández-Sanlés A Ríos-Marco P Romero-López C Berzal-Herranz A Frontiers in Microbiology Functional Information Stored in the Conserved Structural RNA Domains of Flavivirus Genomes 26-32 12 2018 10.2174/1874357901812010026 Petruzziello A The Open Virology Journal Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma 3 03 161-176 2 2017 10.1016/S2468-1253(16)30181-9 Polaris Observatory HCV Collaborators The Lancet. Gastroenterology & Hepatology Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study 01 9 09 1001-1005 45 2017 10.1016/j.ajic.2017.03.011 Egro FM Nwaiwu CA Smith S Harper JD Spiess AM American Journal of Infection Control Seroconversion rates among health care workers exposed to hepatitis C virus-contaminated body fluids: The University of Pittsburgh 13-year experience 2 02 23 14 2021 10.3892/br.2020.1399 Nagao Y Kimura T Nagao H Biomedical Reports Analysis of hepatitis B and C virus infections amongst members of the Dental National Health Insurance Society in the Oita Prefecture 27 Suppl 9 11 S745-S757 222 2020 10.1093/infdis/jiaa534 Falade-Nwulia O Sulkowski MS The Journal of Infectious Diseases Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult 27 10 10 1234-1268 13 2021 10.4254/wjh.v13.i10.1234 Echeverría N Comas V Aldunate F Perbolianachis P Moreno P Cristina J World Journal of Hepatology In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? World Health Organization.Global health sector strategy on viral hepatitis, 2016–2021.Published June 2016. Available at: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf. Accessed 28 November 2022. 1881 1952 1996 Luciw PA 3rd ed. Philadelphia: Lippincott-Raven Human immunodeficiency viruses and their replication. In: Fields BN, editor. Virology 3 05 203-222 43 2016 10.1159/000445852 German Advisory Committee Blood (Arbeitskreis Blut), Subgroup ‘Assessment of Pathogens Transmissible by Blood’ Transfus Med Hemother Human Immunodeficiency Virus (HIV) Accessed 21 April 2021 Global AIDS Update 2019-Communities at the Centre. https://www.unaids.org 1-5 2 3 2019 Mohraz M Amanpour S Alirezaie S Bahari Bandari A Mafi S Oral Health Dental Sci Oral health status and barriers to health care access in Iranian HIV positive patients 18 1 12 657 21 2021 10.1186/s12903-021-02002-3 Shaghaghian S Homayooni M Amin M Rezazadeh F BMC oral health Oral health status of patients infected with human immunodeficiency virus and related factors, Iran: a cross-sectional study Accessed 21 April 2021 Ministry of Health and Medical Education of Iran. http://port.health.gov.ir/mfdc/hiv/default.aspx 01 11 11 a006965 2 2012 10.1101/cshperspect.a006965 Shaw GM Hunter E Cold Spring Harbor Perspectives in Medicine HIV transmission 3 495-510 91 2021 10.1007/s40011-021-01237-y Gupta PK Saxena A Proceedings of the National Academy of Sciences, India. Section B HIV/AIDS: Current Updates on the Disease, Treatment and Prevention 1 02 49-57 27 2022 10.1016/j.idh.2021.10.001 Sotomayor-Castillo C Li C Kaufman-Francis K Nahidi S Walsh LJ Liberali SA Irving E et al Infection, Disease & Health Australian dentists' knowledge, preparedness, and experiences during the COVID-19 pandemic 126-135 8 Suppl 2 2002 10.1034/j.1601-0825.8.s2.3.x McCarthy GM Ssali C. S. Bednarsh H. Jorge J. Wangrangsimakul K. Page-Shafer K. Oral Diseases Transmission of HIV in the dental clinic and elsewhere 26 12 06 4609 17 2020 10.3390/ijerph17124609 Villani FA Aiuto R Paglia L Re D International Journal of Environmental Research and Public Health COVID-19 and Dentistry: Prevention in Dental Practice, a Literature Review